Sugi Predict
/ Targets
/ BRD1
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to BRD1 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD |
PHASE3 | COMPLETED |
| Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients |
PHASE3 | UNKNOWN |
| SMARCA4/2 Inhibitor for POU2F3-Positive SCLC |
PHASE2 | NOT_YET_RECRUITING |
| PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS |
PHASE2 | COMPLETED |
| Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma |
PHASE1/PHASE2 | COMPLETED |
| Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma |
PHASE1/PHASE2 | RECRUITING |
| Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Vorinostat in Children |
PHASE1/PHASE2 | COMPLETED |
| Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes |
PHASE1/PHASE2 | COMPLETED |
| Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma |
PHASE2 | COMPLETED |
| Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial |
PHASE2 | RECRUITING |
| A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load |
PHASE1 | COMPLETED |
| Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors |
PHASE1 | RECRUITING |
| Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome |
PHASE1 | COMPLETED |
| Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer |
PHASE1 | SUSPENDED |
| Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer |
PHASE1 | RECRUITING |
| Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Anti-tumor Activity of SYHA1801 Monotherapy in Patients With Advanced Solid Tumors |
PHASE1 | UNKNOWN |
| A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) |
PHASE1 | COMPLETED |
| Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors |
PHASE1 | COMPLETED |
| Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma |
EARLY_PHASE1 | RECRUITING |
| Expanded Access for Bromodomain and Extra-Terminal (BET) Inhibitor |
nan | NO_LONGER_AVAILABLE |
| A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL |
nan | RECRUITING |
| Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics |
nan | UNKNOWN |
| PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia |
nan | UNKNOWN |
| Autophagy in Systemic Lupus Erythematosus |
nan | UNKNOWN |
| CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma |
nan | UNKNOWN |
| X-chromosome Inactivation, Epigenetics and the Transcriptome |
nan | COMPLETED |
Related proteins — ESM-2 sequence neighbours (a BRD1 binder may also engage these)